Extra ‘triple therapy’ drug for type 2 diabetes

NICE has published final guidance recommending dapagliflozin for treating type 2 diabetes in ‘triple therapy’. Dapagliflozin can be added as a third drug where two drugs for type 2 diabetes are not controlling a person’s blood sugar.

 Professor Carole Longson, director of the NICE centre for health technology evaluation, said: “Having a range of drug options makes it easier to tailor treatments for type 2 diabetes to each person’s individual needs. This new guidance recommends dapagliflozin in triple therapy – only in combination with metformin and a sulfonylurea – which will widen the choice available for people whose diabetes isn’t well controlled with two drugs.”

 

 

Other news

Upcoming Events

AfPP annual residential conference 2017

University of York
10th - 12th August

NPAG - Clinical Engineering and IT Connectivity Conference 2017

Ricoh Arena - Coventry
12th September 2017

Infection Prevention 2017

Manchester Central Convention Complex
18th - 20th September

QIST 2017

The Marriott Hotel Gosforth Newcastle
17th - 18th October

MEDICA

Düsseldorf
13 - 16 November 2017

Latest Issue

Clinical Services Journal

Clinical Services Journal

Jun 2017

Providing an insight into patient experience

Register now to apply for regular copies of Clinical Services Journal and free access to premium content, as well as our regular newsletters.